Rhu GM-CSF for Invasive Fungal Infections

A comprehensive literature search of the PubMed and Embase electronic databases was performed (Figure 1). Search terms consisted of “granulocyte-macrophage colony-stimulating factor” OR “GM-CSF” OR “recombinant granulocyte-macrophage colony-stimulating factor” OR “sargramostim” OR “molgramostim” OR “regramostim” AND “fungal infection” OR “mycosis” AND “case report” to identify case reports published in the English language between January 1, 1990, and March 1, 2022, that evaluated use of rhu GM-CSF as adjunctive therapy in patients with IFDs. Additional studies identified on review of pertinent literature were also included. All cases in which the pathogen, treatment, and efficacy could be fully assessed were included; cases were excluded if no infectious organism was identified. Cases involving rhu GM-CSF for treatment of bacterial, viral, or parasitic infections were excluded.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Chen T.K., Batra J.S., Michalik D.E., Casillas J., Patel R., Ruiz M.E., Hara H., Patel B., Kadapakkam M., Ch'Ng J., Small C.B., Zagaliotis P., Ragsdale C.E., Leal L.O., Roilides E, & Walsh T.J. (2022). Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases. Open Forum Infectious Diseases, 9(11), ofac535.

Publication 2022

Bacterial viral Granulocyte macrophage colony stimulating factor Ifds Infectious Molgramostim Mycosis Parasitic infections Pathogen Patients Regramostim Rhu gm csf

Corresponding Organization : Innovative Clinical Research

Other organizations : Miller Children's & Women's Hospital, University of California, Irvine, University of California, Los Angeles, Hippocration General Hospital, Aristotle University of Thessaloniki

Top 5 similar protocols

Variable analysis

independent variables

Use of rhu GM-CSF as adjunctive therapy in patients with IFDs

dependent variables

Efficacy of rhu GM-CSF treatment

control variables

not explicitly mentioned

controls

no positive or negative controls were specified by the authors

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!